Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

Grozinsky-Glasberg, S; Kaltsas, G; Gur, C; Gal, E; Thomas, D; Fichman, S; Alexandraki, K; Barak, D; Glaser, B; Shimon, I; Gross, DJ

dc.contributor.author	Grozinsky-Glasberg, S	en
dc.contributor.author	Kaltsas, G	en
dc.contributor.author	Gur, C	en
dc.contributor.author	Gal, E	en
dc.contributor.author	Thomas, D	en
dc.contributor.author	Fichman, S	en
dc.contributor.author	Alexandraki, K	en
dc.contributor.author	Barak, D	en
dc.contributor.author	Glaser, B	en
dc.contributor.author	Shimon, I	en
dc.contributor.author	Gross, DJ	en
dc.date.accessioned	2014-03-01T01:57:26Z
dc.date.available	2014-03-01T01:57:26Z
dc.date.issued	2008	en
dc.identifier.issn	0804-4643	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28420
dc.subject.classification	Endocrinology & Metabolism	en
dc.subject.other	ENDOCRINE CELL HYPERPLASIA	en
dc.subject.other	PERNICIOUS-ANEMIA	en
dc.subject.other	ECL CELL	en
dc.subject.other	HYPERGASTRINEMIC PATIENTS	en
dc.subject.other	NEUROENDOCRINE TUMORS	en
dc.subject.other	ATROPHIC GASTRITIS	en
dc.subject.other	ANTRECTOMY	en
dc.subject.other	OCTREOTIDE	en
dc.subject.other	MANAGEMENT	en
dc.subject.other	DYSPLASIA	en
dc.title	Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Background: Gastric carcinoid tumours type 1 (GCA1) originate from hyperplastic enterochromaflin-like (ECL) cells secondary to hypergastrinaemia. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. We conducted a multicentre prospective study to assess the effects of long-acting SSA on hypergastrinaemia and ECL-cell proliferation in patients with GCA1. Methods: We studied 15 patients with GCA1 treated with monthly long-acting release octreotide (LAR) (20-30 mg; n = 14) or Lanreotide 90 mg (n = 1) for at least 6 months. Patients had serum gastrin and chromogranin A measurements performed and biopsies taken from both tumours and surrounding mucosa before. and every 6-12 months following treatment. Sections were immunostained for neuroendocrine markers. The cell proliferation index Ki-67, intensity of staining before and after treatment and the degree of gastric wall invasion were also assessed. Results: All patients tolerated treatment well (mean follow-up of 18 months). In 11 patients (73%), a complete disappearance of the tumours at 1 year of treatment was observed on endoscopy, while in normalized in 25% of patients, and were reduced by more than 80% in the remaining 75%. Conclusions: Treatment with SSAs in GCA1 leads to a substantial tumour load reduction, with a concomitant decrease of serum gastrin levels. Our data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1.	en
heal.publisher	BIO SCIENTIFICA LTD	en
heal.journalName	EUROPEAN JOURNAL OF ENDOCRINOLOGY	en
dc.identifier.isi	ISI:000260169900017	en
dc.identifier.volume	159	en
dc.identifier.issue	4	en
dc.identifier.spage	475	en
dc.identifier.epage	482	en